EQRX aims for biopharma Spac record
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
Venture investors still love drug developers
Biopharma scores a $5bn quarter as another big year builds for venture financing.
What pandemic? Biotech floats break records
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
Added firepower could signal a spending spree for Sanofi
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
TG pulls victory from the jaws of defeat
The Unity-CLL trial shows ublituximab plus umbralisib conferring an unexpected progression-free survival benefit.
Biopharma venture financing retreats, but not by much
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
